| P50 | author | Florian Schuetz | Q91159198 |
| | Peter Sinn | Q37609928 |
| P2093 | author name string | Marc Sütterlin | |
| | Markus Wallwiener | |
| | Andreas Schneeweiss | |
| | Christof Sohn | |
| | Andreas Hartkopf | |
| | Ralph Wirtz | |
| | Stefan Stefanovic | |
| | Thomas M Deutsch | |
| | Michael K Bohlmann | |
| P2860 | cites work | Circulating Tumour Cells, Circulating Tumour DNA and Circulating MicroRNA in Metastatic Breast Carcinoma - What is the Role of Liquid Biopsy in Breast Cancer? | Q47150180 |
| | Impact of apoptotic circulating tumor cells (aCTC) in metastatic breast cancer. | Q48325627 |
| | HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial | Q51751068 |
| | Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update | Q57130157 |
| | Prognostic value of estrogen receptor α and progesterone receptor conversion in distant breast cancer metastases | Q60529806 |
| | Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival | Q79954604 |
| | Circulating tumor cells in patients with breast cancer dormancy | Q81208525 |
| | Circulating tumor cells in metastatic breast cancer: from prognostic stratification to modification of the staging system? | Q81952877 |
| | Circulating tumor cells in breast cancer | Q26774808 |
| | Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing | Q27860948 |
| | Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial | Q28305038 |
| | Circulating tumor cells, disease progression, and survival in metastatic breast cancer | Q29619276 |
| | Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 | Q30543788 |
| | Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data | Q30779447 |
| | Prognostic relevance of induced and spontaneous apoptosis of disseminated tumor cells in primary breast cancer patients | Q33746929 |
| | Cytogenetic evidence that circulating epithelial cells in patients with carcinoma are malignant. | Q34138373 |
| | Serial enumeration of circulating tumor cells predicts treatment response and prognosis in metastatic breast cancer: a prospective study in 393 patients | Q34485182 |
| | Receptor conversion in distant breast cancer metastases | Q34989060 |
| | Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment | Q35558126 |
| | Presence of apoptotic and nonapoptotic disseminated tumor cells reflects the response to neoadjuvant systemic therapy in breast cancer | Q35605856 |
| | Technical validation of an RT-qPCR in vitro diagnostic test system for the determination of breast cancer molecular subtypes by quantification of ERBB2, ESR1, PGR and MKI67 mRNA levels from formalin-fixed paraffin-embedded breast tumor specimens. | Q36070547 |
| | Comparison of the HER2, estrogen and progesterone receptor expression profile of primary tumor, metastases and circulating tumor cells in metastatic breast cancer patients | Q36085375 |
| | Epithelial-mesenchymal transition and stem cell markers in patients with HER2-positive metastatic breast cancer. | Q36406697 |
| | Apoptosis: a relevant tool for anticancer therapy | Q36499642 |
| | Contrasting breast cancer molecular subtypes across serial tumor progression stages: biological and prognostic implications | Q36545146 |
| | Biological subtyping of early breast cancer: a study comparing RT-qPCR with immunohistochemistry. | Q36994974 |
| | Detection and characterization of circulating tumor cells in blood of primary breast cancer patients by RT-PCR and comparison to status of bone marrow disseminated cells | Q37360230 |
| | Circulating and disseminated tumor cells in the management of breast cancer | Q37552483 |
| | Receptor conversion in metastatic breast cancer: a prognosticator of survival | Q37687736 |
| | Apoptotic circulating tumor cells in early and metastatic breast cancer patients | Q39137881 |
| | Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay | Q39162225 |
| | M30 neoepitope expression in epithelial cancer: quantification of apoptosis in circulating tumor cells by CellSearch analysis. | Q39639547 |
| | Monitoring apoptosis and Bcl-2 on circulating tumor cells in patients with metastatic breast cancer. | Q41134672 |
| | Therapeutic intervention based on circulating tumor cell phenotype in metastatic breast cancer: concept of the DETECT study program | Q41382683 |
| | Tumor biomarker conversion between primary and metastatic breast cancer: mRNA assessment and its concordance with immunohistochemistry | Q41612814 |
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | apoptotic process | Q14599311 |
| | metastatic breast cancer | Q12859063 |
| P304 | page(s) | 342 | |
| P577 | publication date | 2019-03-11 | |
| P1433 | published in | Cancers | Q27722963 |
| P1476 | title | Molecular Subtype Conversion between Primary and Metastatic Breast Cancer Corresponding to the Dynamics of Apoptotic and Intact Circulating Tumor Cells | |
| P478 | volume | 11 | |